Abstract | INTRODUCTION: METHODS: Data from a study in 123 patients with heterozygous FH and coronary artery disease on maximally tolerated lipid-lowering therapy were used to evaluate in what percentage adding mipomersen resulted in lipid-levels below apheresis-thresholds. Different thresholds were tested: LDL-C ≥ 2.59 mmol/l, ≥ 3.36 mmol/l, ≥ 4.14 mmol/l, Lp(a) ≥ 60 mg/dl. RESULTS:
Mipomersen decreased LDL-C by 28% (baseline 153 mg/dl), Lp(a) by 21% (baseline 45 mg/dl) (placebo no effect). Mipomersen reduced the percentage of patients with LDL-C ≥ 4.14 mmol/l from 39 to 2%, with LDL ≥ 3.36 mmol/l from 62 to 16%, with LDL ≥ 2.59 mmol/l from 98 to 54%, and with Lp(a) ≥ 60 mg/dl from 39 to 23%. SUMMARY: When added to maximally tolerated lipid-lowering therapy, mipomersen may reduce the necessity for apheresis in many of these patients. In Germany, the threshold for apheresis for LDL typically is 2.59 mmol/l, for Lp(a) 60 mg/dl. Almost 50% of the patients could avoid apheresis with the addition of mipomersen. Further studies are warranted to evaluate whether patients who qualify for apheresis could be adequately controlled with mipomersen.
|
Authors | Anja Vogt, Klaus G Parhofer |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 14
Issue 6
Pg. 691-7
(Apr 2013)
ISSN: 1744-7666 [Electronic] England |
PMID | 23477485
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticholesteremic Agents
- Apolipoproteins B
- Cholesterol, LDL
- Oligonucleotides
- mipomersen
|
Topics |
- Aged
- Anticholesteremic Agents
(pharmacology, therapeutic use)
- Apolipoproteins B
(biosynthesis)
- Blood Component Removal
(methods)
- Cholesterol, LDL
(blood)
- Coronary Artery Disease
(drug therapy, physiopathology)
- Female
- Germany
- Humans
- Hyperlipoproteinemia Type II
(drug therapy, physiopathology)
- Male
- Middle Aged
- Oligonucleotides
(pharmacology, therapeutic use)
|